At-home molecular testing

Post date: 2024-11-13 04:45:03
Views: 33
I seem to remember someone here recommending a tabletop at-home device for Covid testing (maybe NAAT?) that's approved in the European market but not in the US. Can someone here remind me?

Context: We've got an ambiguous rapid antigen test result for COVID in our house. The line is so faint that it is not pink or red, although two out of three of us see something there, like a shadow. We'd hoped to confirm with PCR so we can plan (eg what are the chances we'll need to cancel our Thanksgiving trip to see my elderly mother in her nursing home?) but we learned that molecular testing isn't offered in our region anymore.

I know that I might not be able to buy anything that is immediately useful for this situation, but since Covid isn't going anywhere, maybe this is worth an investment. We do plan to follow up with more RATs over the next few days.

We do know that CDC guidelines don't require us to care. I'm not worried for my kid at all, she's only mildly ill. I just want to do the right things to limit spread, here and in future.
Please click Here to read the full story.
 
Other Top and Latest Questions:
NY Fed President Williams says some 'technical factors' distorted November's CPI reading downward
Wall Street's top stock picks for 2026: Mizuho’s under-the-radar name that could more than triple in value
Zelenskyy favors U.S. proposal of three-way talks if it produces results in ending war with Russia
S&P 500 coasts to a third year of superior returns. Three key questions for Wall Street entering 2026
Lucid's big SUV arrives with high expectations, and big risks
Here’s where the stock market is headed in 2026, according to Wall Street’s top strategists
Mortgage rewards credit cards are disappearing. Here's what to do next
Jim Cramer is encouraged by Nvidia-China reports and dismisses a Honeywell charge
Brick trophies, a life-size pink Cadillac and a team sponsorship: Why Lego is going all in on F1
Starbucks turnaround will take time. This options strategy works if shares remain range-bound